Kinimmune, Inc.

Kinimmune is a clinical-stage biopharmaceutical company that develops intratumoral immunostimulants designed to enhance the efficacy of cancer treatments, particularly checkpoint inhibitors, in solid tumors. The company utilizes proprietary tissue-retentive formulations to keep therapeutic compounds at the site of injection, which allows for potent localized immune activation while minimizing systemic exposure and associated off-target adverse effects. Their technology aims to turn immune-cold tumors into hot environments, potentially expanding the range of patients who can benefit from immunotherapy.

Founded in 2020 and headquartered in St. Louis, the company originated from research at the University of Kansas and Washington University in St. Louis. Their pipeline includes KIN-101, which is in clinical development, along with preclinical and discovery-stage programs like KIN-102. Kinimmune has received non-dilutive funding, including awards from the National Cancer Institute, to support the advancement of these candidates. By leveraging pharmaceutical components with established safety profiles, the company seeks to create quick-to-market interventions that address unmet medical needs for patients with solid tumors.